Park City, Utah, United States
Physician-leader with more than a decade of experience in orthopedic surgery, medical affairs, clinical research, and cross-functional product strategy across medical device, biopharma, and digital health sectors. I have led clinical strategy for Class III musculoskeletal devices, including an implant that received FDA Breakthrough Device Designation. My work includes building global clinical trial infrastructure, guiding evidence strategy, driving surgeon engagement, and supporting product development through real-world insights. My focus is on translating clinical evidence into action. This includes designing and executing training programs, informing design improvements through physician feedback, and supporting launch readiness through publication and education strategy. I also bring expertise in digital health and AI evaluation, helping teams assess patient-facing technologies for clinical impact and safety. Key areas of focus: • Medical affairs leadership, evidence generation, and lifecycle planning • Orthopedic implants, spine, sports medicine, and osteoarthritis therapeutics • Cross-functional collaboration with R&D, regulatory, and commercial teams • Digital health, patient communication, and evaluation of AI-powered tools
Snorkel’s data annotation projects advance cutting-edge AI research in reasoning, evaluation, and problem-solving—improving the utility of large language models (LLMs) in academia, industry, and beyond. https://snorkel.ai/ Authored and validated original, high-difficulty problems, applying subject matter expertise in health policy/economics, oncology, orthopedics, otolaryngology, radiology, sports medicine, and urology. Contributed to a proprietary dataset of high-rigor challenges used in AI fine-tuning, benchmarking, and reinforcement learning. Advanced AI’s depth of knowledge and ability to reason, validate its own solutions, and produce rigorous justifications and academically acceptable solutions, directly improving interpretability and correctness in LLM-based problem solving. Uncovered failure modes in deductive logic, computation, and mathematical reasoning, contributing to the evolution of AI's mathematical cognition, influencing model fine-tuning strategies and shaping the next generation of AI reasoning benchmarks.
Strategic advisor to health technology companies, academic teams, and startups across medical devices, digital health, and patient engagement. Trusted for translating clinical insight into actionable strategy, credible messaging, and real-world validation. Highlights include: • Leading outcomes strategy for an AI-driven wellness platform, ensuring alignment between product vision, clinical endpoints, and market expectations • Building a structured patient education library for orthopedic surgery, improving comprehension, engagement, and consent processes • Advising health AI and oncology startups on clinical validation, evidence generation, and regulatory differentiation • Contributing medical oversight to large language model (LLM) development, enhancing accuracy, reasoning, and trust in health-facing tools • Authoring a peer-reviewed framework for evaluating the clinical safety of generative AI in consumer health
Early-stage medical technology firm pioneering bone disease treatments; 2024 revenues $11.2M and 53 employees. https://www.agnovos.com/ Served as Head of Medical Affairs for pre-market spine device platform to treat osteoporotic vertebral compression fractures. Supported pre- and post-market hip product platform for the prevention of hip fractures. Directed global spine product lifecycle strategies—drove cross-functional spine project teams (regulatory, R&D/engineering, marketing). Developed physician-training telehealth training program for clinical trials. Built and maintained relationships with trusted health ecosystem partners globally. Led spine scientific publication and content strategy for congresses, advisory boards, and scientific meetings.
Formerly Samumed: https://www.businessinsider.com/samumed-raises-438-million-at-12-billion-valuation-2018-8 A biopharma firm focused on sports medicine/oncology; $26M in revenue (raised $884M; second only to Moderna in private financing in 2018) and 174 employees. Disseminated pre-clinical and clinical data related to company’s Phase 3 small-molecule wnt pathway-modulating therapy to treat osteoarthritis through peer-reviewed publications, conference symposia, podium presentations, and advisory boards, supporting drug launch, commercialization and consumer education. Engaged orthopedic/sports medicine and rheumatology key opinion leaders internationally. Co-authored winning presentation for international Biologic Association "Shark Tank"-style competition, pitching innovative biologics solution to industry-leading physicians and investors—securing top score for clinical and commercial potential. Provided medical and clinical expertise to support therapy pipelines for oncology, neurology, and diabetes.